KOSELUGOHCP.COM: Keyword Density Checker

Total words: 4059 | 2-word phrases: 1050 | 3-word phrases: 1213 | 4-word phrases: 1273

PAGE INFO

Title	Try to keep the title under 60 characters (51 characters) Koselugo® (selumetinib) \| Official HCP Website
Description	Try to keep the meta description between 50 - 160 characters (246 characters) Koselugo® (selumetinib) is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Please see full Prescribing Information.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

#	Keyword	Frequency	Density
1	koselugo based on	4	0.33%
2	permanently discontinue koselugo	4	0.33%
3	based on severity	4	0.33%
4	on severity of	4	0.33%
5	severity of adverse	4	0.33%
6	of adverse reaction	4	0.33%
7	prior to initiating	4	0.33%
8	withhold reduce dose	4	0.33%
9	inoperable plexiform neurofibromas	3	0.25%
10	alexion pharmaceuticals inc	3	0.25%
11	discontinue koselugo based	3	0.25%
12	during treatment with	3	0.25%
13	to initiating koselugo	3	0.25%
14	age 10 living	3	0.25%
15	10 living with	3	0.25%
16	living with nf1	3	0.25%
17	reduce dose or	3	0.25%
18	neurofibromatosis type 1	3	0.25%
19	icon of a	3	0.25%
20	in patients with	3	0.25%
21	lvef obtain an	2	0.16%
22	use of koselugo	2	0.16%
23	or permanently discontinue	2	0.16%
24	a decrease in	2	0.16%
25	safety signals were	2	0.16%
26	new safety signals	2	0.16%
27	no new safety	2	0.16%
28	resulting in dose	2	0.16%
29	66 3350 of	2	0.16%
30	3350 of patients	2	0.16%

#	Keyword	Frequency	Density
1	on severity of adverse	4	0.31%
2	based on severity of	4	0.31%
3	koselugo based on severity	4	0.31%
4	withhold reduce dose or	3	0.24%
5	prior to initiating koselugo	3	0.24%
6	age 10 living with	3	0.24%
7	severity of adverse reaction	3	0.24%
8	discontinue koselugo based on	3	0.24%
9	permanently discontinue koselugo based	3	0.24%
10	10 living with nf1	3	0.24%
11	koselugo in patients with	2	0.16%
12	the median duration of	2	0.16%
13	and as clinically indicated	2	0.16%
14	with koselugo and for	2	0.16%
15	safety signals were identified	2	0.16%
16	inoperable plexiform neurofibromas pn	2	0.16%
17	during treatment with koselugo	2	0.16%
18	years of age and	2	0.16%
19	of age and older	2	0.16%
20	treatment with koselugo and	2	0.16%
21	sam is not a	2	0.16%
22	koselugo and for 1	2	0.16%
23	koselugo with a strong	2	0.16%
24	concomitant use of koselugo	2	0.16%
25	use of koselugo with	2	0.16%
26	3350 of patients achieved	2	0.16%
27	66 3350 of patients	2	0.16%
28	the safety of koselugo	2	0.16%
29	of koselugo with a	2	0.16%
30	with a strong or	2	0.16%
31	for 1 week after	2	0.16%
32	a strong or moderate	2	0.16%
33	strong or moderate cyp3a4	2	0.16%
34	symptomatic inoperable plexiform neurofibromas	2	0.16%
35	interruption or dose reduction	2	0.16%
36	selumetinib plasma concentrations which	2	0.16%
37	plasma concentrations which may	2	0.16%
38	and for 1 week	2	0.16%
39	with neurofibromatosis type 1	2	0.16%
40	median duration of exposure	2	0.16%

#	URL	Whois	Check
1	https://us-aereporting.astrazeneca.com	Whois	astrazeneca.com
2	https://fda.gov/medwatch	Whois	fda.gov
3	https://alexion.com/Documents/koselugo_uspi.pdf	Whois	alexion.com
4	https://alexion.com/contact-alexion	Whois	alexion.com
5	http://alexion.com/	Whois	alexion.com
6	https://alexion.com/Legal#CADSR	Whois	alexion.com
7	https://alexion.com/Legal	Whois	alexion.com
8	https://alexion.com/Documents/koselugo_uspi.pdf	Whois	alexion.com